A randomized crossover study to evaluate Ro 115–1240, a selective α 1A/1L ‐adrenoceptor partial agonist in women with stress urinary incontinence
D.M. Musselman, Anthony P.D.W. Ford, Daniel Gennevois et al. · British Journal of Urology · 2003
OBJECTIVES: To investigate the potential therapeutic benefits of the selective alpha1A/1l-adrenoceptor partial agonist Ro 115-1240 in women with mild-to-moderate stress urinary incontinence (SUI). PATIENTS AND METHODS: Thirty-seven women with mild-to-moderate SUI were enrolled in a randomized, placebo-controlled crossover study. Patients received 1.5 mg Ro 115-1240 twice daily or matching placebo for 2 or 4 weeks. Voiding diaries were used to record the number of SUI episodes, urge incontinence episodes and pads used. Sitting blood pressures and heart rate were recorded at each visit. RESULTS: Ro 115-1240 was associated with a significantly lower mean weekly number of SUI episodes than placebo (8.4 vs 6.0; P= 0.0079), a 28% relative improvement over placebo. There was also a significantly lower mean number of pads used and wet pads changed/week with Ro 115-1240 than with placebo (P = 0.0055 and 0.0066, respectively). The most frequently reported treatment-emergent adverse events were scalp tingling, headache, chills, piloerection, and pruritus. Generally these events were transient and mild to moderate. There was a slightly lower mean sitting heart rate with Ro 115-1240 than with placebo, but no difference in mean systolic or diastolic blood pressure between treatments. CONCLUSIONS: This study suggests that selective alpha1A/1l-adrenoceptor partial agonists have the potential to improve the symptoms of SUI with little or no cardiovascular effect. These results are encouraging and a randomized controlled trial of Ro 115-1240 in a larger population with SUI is warranted to substantiate these findings.
Cited by 51 works. doi:10.1111/j.1464-410x.2004.04560.x
Authors
- D.M. Musselman
- Anthony P.D.W. Ford
- Daniel Gennevois
- Margaret L. Harbison
- Ahmad Mokatrin
- Randall R. Stoltz
- David R. Blue
References
- Pharmacology of lower urinary tract smooth muscles and penile erectile tissues.
- International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update.
- Duloxetine versus placebo in the treatment of stress urinary incontinence
- Conservative treatment of stress urinary incontinence in women: a systematic review of randomized clinical trials
- Pelvic floor electrical stimulation in the treatment of genuine stress incontinence: A multicenter, placebo-controlled trial
- Midodrine: a role in the management of neurocardiogenic syncope
- Pharmacological subclassification of α1‐adrenoceptors in vascular smooth muscle
- Ephedrine in treatment of urinary incontinence
- α1-Adrenoceptor subclassification in vascular smooth muscle
- RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification.